Shares of InVitae Corp (NYSE:NVTA) have been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $14.50.

Several equities research analysts have recently issued reports on the company. BidaskClub raised InVitae from a “hold” rating to a “buy” rating in a research report on Thursday, October 12th. Zacks Investment Research raised InVitae from a “hold” rating to a “strong-buy” rating and set a $11.00 target price for the company in a research report on Wednesday, October 11th. Ladenburg Thalmann Financial Services assumed coverage on InVitae in a research report on Friday. They set a “buy” rating and a $15.00 target price for the company. Finally, Leerink Swann decreased their target price on InVitae from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday, November 7th.

A number of institutional investors and hedge funds have recently made changes to their positions in NVTA. Verity Asset Management Inc. increased its holdings in InVitae by 0.8% in the 2nd quarter. Verity Asset Management Inc. now owns 10,607 shares of the medical research company’s stock worth $101,000 after acquiring an additional 81 shares during the last quarter. Lakeview Capital Partners LLC purchased a new stake in InVitae in the 3rd quarter worth about $117,000. Gabelli Funds LLC purchased a new stake in InVitae in the 3rd quarter worth about $131,000. State Board of Administration of Florida Retirement System purchased a new stake in InVitae in the 3rd quarter worth about $133,000. Finally, CAPROCK Group Inc. purchased a new stake in InVitae in the 3rd quarter worth about $139,000. 64.67% of the stock is owned by institutional investors.

Shares of InVitae (NVTA) traded up $0.29 during trading on Friday, hitting $9.82. The stock had a trading volume of 383,700 shares, compared to its average volume of 349,033. InVitae has a 1 year low of $2.70 and a 1 year high of $9.90. The stock has a market cap of $530.99 and a price-to-earnings ratio of -3.85. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.33.

TRADEMARK VIOLATION NOTICE: “InVitae Corp (NVTA) Receives Consensus Rating of “Hold” from Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/05/invitae-corp-nvta-receives-consensus-rating-of-hold-from-brokerages-2.html.

About InVitae

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.